FDA ESG NextGen Launches April 14th, 2025: Are You Prepared?

The Food and Drug Administration (FDA) has announced that the modernised FDA ESG NextGen system will officially go live on April 14th, 2025, at 9:00 AM ET.

This FDA Electronic Submissions Gateway transition aims to enhance the electronic submission process with improved security, functionality, and tracking features.

FDA ESG NextGen Launches: Key Dates to Note

• April 12th–14th, 2025: The FDA will not accept any submissions during this period as the legacy ESG system is decommissioned.
• April 14th, 2025 (9:00 AM ET): ESG NextGen becomes operational and will resume accepting both test and production submissions.

Companies are advised to ensure full preparedness for this FDA ESG NextGen transition to avoid any disruption in regulatory workflows.

PharSafer Is Ready: FDA ESG NextGen Launches

Demonstrating our commitment to proactive compliance and client support, PharSafer has.

• Conducted thorough testing with the new FDA ESG NextGen system.

• Received successful acknowledgements from the FDA for submitted test packages.

• Ensured our systems and teams are fully prepared for the April 14th go-live.

What’s New in FDA ESG NextGen?

• A streamlined FDA Unified Submission Portal acts as the direct WebTrader replacement FDA users must adopt.

• Real-time tracking and reporting for enhanced submission visibility.

• Enhanced cybersecurity featuring ESG NextGen multi-factor authentication.

• New API functionality to support automation and integration.

• Continued support for AS2 submissions FDA pipelines to ensure a smooth transition.

Recommended Actions for MAHs and Regulatory Teams:

• Finalise readiness for FDA ESG NextGen by aligning internal systems and processes.

• Account for the FDA submission blackout period (April 12th–14th) in submission planning.

• Stay updated with reliable FDA regulatory intelligence to ensure ongoing regulatory submission compliance.

• Contact esgngsupport@fda.hhs.gov if communication from the FDA has not been received.

 

PharSafer is committed to supporting our clients during this transition.

If you have any questions or require further guidance, please contact us directly: enquiries@pharsafer.com